cnt
A3

11. (new) The method of claim 6, wherein the compound identified is a protein.

12. (new) The method of claim 6, wherein the compound identified is a peptide.

REMARKS

The specification has been amended to reflect that the parent application has now issued as U.S. Patent No. 6,153,432.

By Office Action dated June 15, 2001, the Examiner restricted the prosecution of the pending claims to one of claims under 35 U.S.C. § 121. Applicants hereby elect the invention of Group VI without traverse. Accordingly, Applicants have amended claim 6 and added new claims 7-11. Support for the newly added claims can be found generally within the specification, and for example, in the Detailed Description of the Invention at and for example, at page 15, lines 29-31, page 16, lines 18-29, and page 9 generally.

Applicants believe that the claims are now in condition for allowance, and earnestly solicit an early notification of same. The Examiner is invited to contact the undersigned at the below listed number to discuss this case, if such discussion would expedite the prosecution of this case.

Respectfully submitted,



Sherry M. Knowles
Reg. No. 33,052

King & Spalding
191 Peachtree St.
Atlanta, GA 30303
404-572-3531
404-572-5145 (fax)

Marked-up Version of Specification

This application is a divisional of U.S. Application Serial No. 09/240,029, filed on January 29, 1999, which is now U.S. Patent No. 6,153,432.

Marked-up Version of the Claims

6. A method comprising:

(i) obtaining a greater than 90% enriched population of isolated differentiated adipocytes,

(ii) and identifying a protein secreted by the enriched population.

~~[method for identifying polypeptides secreted from cultured human adipocytes prepared from preadipocytes using a method comprising:~~

~~a) plating isolated human preadipocytes at a density of about 25,000 to 30,000 cells/cm^2 in a preadipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;~~

~~b) incubating said cells at about 37°C for about 4-48 hours until said cells are about 95-100% confluent;~~

~~c) replacing said preadipocyte medium with a differentiation medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose, 0.2 to 0.5 mM isobutylmethylxanthine; 100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a gluycocorticoid; and a concentration of a PPARγ agonist or RXR agonist effective to stimulate differentiation of human preadipocytes;~~

~~d) incubating said cells at about 37°C for about 2-4 days;~~

~~e) replacing said differentiation medium with an adipocyte medium comprising a defined cell culture medium having or supplemented with 1.0-4.5 g/liter glucose;~~

~~100 nM to 1 μM insulin, or an equivalent amount of an insulin analogue; 16 nM to 1 μM of a glucocorticoid; and~~

~~f) incubating said cells at about 37°C for about 1-2 weeks and refeeding said cells with said adipocyte medium at least every 3-4 days;~~

~~wherein said preadipocyte medium, said differentiation medium and said adipocyte medium are maintained at a pH of at least 7.0 to 7.6 when in contact with said cells; and wherein said method comprises fractionating the polypeptides which are secreted~~].